Why Rwanda?

WHO Maturity Level 3 Certification: Rwanda is one of only 8 African countries with a WHO-certified regulatory agency, ensuring globally accepted trial oversight aligned with FDA and EMA standards.
rwandafda.gov.rw

2-Month Regulatory Approval Timeline – Among the fastest in Africa, significantly reducing study startup delays.

Ethical Oversight in Clinical Trials: All clinical trials in Rwanda are required to obtain ethical clearance from the Rwanda National Ethics Committee. This process ensures that studies are conducted in accordance with international ethical standards, safeguarding participant rights and well-being. rwandafda.gov.rw

50%+ Lower Costs – Rwanda offers high-quality clinical research at half the cost of U.S. and European trial sites, without compromising data integrity.

50% Faster Patient Recruitment – With an underserved patient population and low trial density, Rwanda enables rapid participant enrollment, avoiding the long wait times seen in saturated trial regions.

150,000+ Patient Database – Immediate access to a large, diverse, ideal for faster recruitment in Phase I–III trials.

Proven Track Record –Rwanda has emerged as a premier destination for Phase I–IV clinical trials​, collaborating with global sponsors such as Moderna​, Janssen (Johnson & Johnson)​, Novartis​, and IAVI. The country’s research contributions span mRNA HIV vaccines​, mosaic HIV and Ebola vaccines​​, malaria therapies​.

Strong Government Investment in Research & Development – Rwanda has prioritized biotech, life sciences, and clinical research infrastructure, fostering an environment conducive to high-quality, globally recognized clinical trials.

Growing Pharmaceutical Industry – The country is attracting major global sponsors investing in biomanufacturing, vaccine production, and clinical trial capacity, solidifying Rwanda as a hub for cutting-edge drug development.

Advanced Healthcare & Research Infrastructure – Rwanda has made significant investments in state-of-the-art research hospitals, oncology centers, and trial sites, ensuring world-class facilities for Phase I–III trials.